Dard, Céline
Swale, Christopher
Brenier-Pinchart, Marie-Pierre
Farhat, Dayana C.
Bellini, Valeria
Robert, Marie Gladys
Cannella, Dominique
Pelloux, Hervé
Tardieux, Isabelle
Hakimi, Mohamed-Ali https://orcid.org/0000-0002-2547-8233
Funding for this research was provided by:
European Research Council (614880)
FRM (FRM FDT201904008364)
Agence Nationale de la Recherche (ANR-18-CE15-0023, ANR-11-LABX-0024)
Article History
Received: 30 May 2020
Accepted: 12 January 2021
First Online: 9 February 2021
Ethics approval and consent to participate
: Human sera were retrospectively selected from the biobank collection of the Parasitology-Mycology Clinical Laboratory in Grenoble Alpes University Hospital in France. This biobank is registered with the French Ministry of Health under the number DC-2008-582. The Quality Management System is applied in the Parasitology-Mycology Clinical Laboratory in the University Grenoble Alpes Hospital and our laboratory is accredited according to ISO 15189 standard. All the sera were collected in agreement with the institution and after no patient’s opposition.Mouse care and experimental procedures were performed under pathogen-free conditions in accordance with established institutional guidance and approved protocols from the Institutional Animal Care and Use Committee of the University Grenoble Alpes (agreement n°B3851610006).
: M.-A.H., C. D., C. S., and M.-P. B.-P. are co-inventors on a patent application related to this work that covers the use of BCLA as a biomarker for diagnosis of chronic toxoplasmosis in humans. Inserm and its valorization subsidiary Inserm-Transfert are involved in the pending patent application. The other authors declare that they have no competing interests.